UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2025
Commission file number: 001-37891
AC IMMUNE SA
(Exact Name of Registrant as Specified in Its Charter)
EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.
Form 20-F ☒ Form
40-F ☐
On September 4, 2025, AC Immune SA (“AC
Immune”) issued a press release reporting that, following a strategic review by executive management, AC Immune is sharpening
its focused investment on its most important assets. These include its three clinical-stage active immunotherapy programs, two of which
are in ongoing pharma collaborations, and its most promising small molecule programs targeting NLRP3 and Tau. As a result, AC Immune will
reduce its workforce by around 30% and extend its cash for operations to the end of the third quarter of 2027.
A copy of the press release is attached as Exhibit
99.1 to this Report on Form 6-K.
This Report on Form 6-K shall be deemed to be
incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655 and 333-277940) and Form S-8
(File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed,
to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
AC IMMUNE SA |
| |
|
|
|
| |
|
|
|
| |
By: |
/s/ Andrea Pfeifer |
| |
|
Name: |
Andrea Pfeifer |
| |
|
Title: |
Chief Executive Officer |
| |
|
|
|
| |
|
|
|
| |
By: |
/s/ Christopher Roberts |
| |
|
Name: |
Christopher Roberts |
| |
|
Title: |
Chief Financial Officer |
Date: September 4, 2025
EXHIBIT INDEX
| Exhibit Number |
Description |
| 99.1 |
Press release dated September 4, 2025 |
